Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your agenda.
This session is in your agenda. Click to remove it
Back
Favorite
0
Like
Facebook
Tweet
Print
D. Lynn Kirkpatrick, PhD
CEO
Ensysce Biosciences
La Jolla, California
Disclosure information not submitted.
Presentation(s):
Intranasal and Oral Human Abuse Potential (HAP) Studies with PF614: A Novel Trypsin Activated Abuse Protected (TAAP) Extended-Release Oxycodone Prodrug
POSTER ABSTRACT
PF614-MPAR: A Novel Trypsin Activated Abuse Protected (TAAP) Extended-Release Oxycodone Prodrug with Overdose Protection
POSTER ABSTRACT
